ICLUSIG (ponatinib) tablets

Iclusig is FDA-approved to treat acute lymphoblastic leukemia (ALL). The drug is used to treat ALL in adults whose cancer cells have a certain gene mutation called the Philadelphia chromosome (Ph+ ALL). Cancer cells with the Philadelphia chromosome make a protein that helps cancer cells grow and divide. Brand Name: ICLUSIG (ponatinib) tablets. FDA approved ponatinib (brand name ICLUSIG) is not (yet) registered or available in India but on request Indian patient can buy ICLUSIG at the lowest price.

ICLUSIG (ponatinib) tablets Price In India and Overseas
ICLUSIG (ponatinib) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ICLUSIG (ponatinib) tablets

Ponatinib is a medication for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.

A drug used to treat adults with certain types of chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Iclusig blocks BCR::ABL and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Iclusig is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called ponatinib hydrochloride.

A drug used to treat adults with certain types of chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib hydrochloride blocks BCR::ABL and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Ponatinib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Iclusig.

Drug (Brand / Generic): ICLUSIG / ponatinib
Current Indications: chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).
Marketed by:: ARIAD Pharmaceuticals, Inc
Approval Date: 2012

Dosage forms and strengths of ADCETRIS (brentuximab vedotin).
Tablets: 15 mg and 45 mg

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.